{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:10:34Z","timestamp":1794305434408,"version":"4.9.0"},"reference-count":150,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Spinal muscular atrophy linked to chromosome 5 (SMA-5q) is an autosomal recessive genetic disease caused by mutations in the SMN1. SMA-5q is characterized by progressive degeneration of the spinal cord and bulbar motor neurons, causing severe motor and respiratory impairment with reduced survival, especially in its more severe clinical forms. In recent years, highly effective disease-modifying therapies have emerged, either acting by regulating the splicing of exon 7 of the SMN2 gene or adding a copy of the SMN1 gene through gene therapy, providing a drastic change in the natural history of the disease. In this way, developing therapeutic guides and expert consensus becomes essential to direct the use of these therapies in clinical practice. This consensus, prepared by Brazilian experts, aimed to review the main available disease-modifying therapies, critically analyze the results of clinical studies, and provide recommendations for their use in clinical practice for patients with SMA-5q. This consensus also addresses aspects related to diagnosis, genetic counseling, and follow-up of patients under drug treatment. Thus, this consensus provides valuable information regarding the current management of SMA-5q, helping therapeutic decisions in clinical practice and promoting additional gains in outcomes.<\/jats:p>","DOI":"10.1055\/s-0044-1779503","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T01:06:48Z","timestamp":1707181608000},"page":"001-018","source":"Crossref","is-referenced-by-count":13,"title":["Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy"],"prefix":"10.1055","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4991-6760","authenticated-orcid":false,"given":"Edmar","family":"Zanoteli","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, Departamento de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-4354","authenticated-orcid":false,"given":"Alexandra Prufer de Queir\u00f3z Campos","family":"Araujo","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Faculdade de Medicina, Departamento de Pediatria, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1232-5896","authenticated-orcid":false,"given":"Michele Michelin","family":"Becker","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas de Porto Alegre, Departamento de Pediatria, Unidade de Neurologia Infantil, Porto Alegre RS, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8253-0501","authenticated-orcid":false,"given":"Clarisse Pereira Dias Drumond","family":"Fortes","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Instituto de Puericultura e Pediatria Martag\u00e3o Gesteira, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0898-2419","authenticated-orcid":false,"suffix":"Jr.","given":"Marcondes Cavalcante","family":"Fran\u00e7a","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas, Faculdade de Ci\u00eancias M\u00e9dicas, Departamento de Neurologia, Campinas SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6987-3086","authenticated-orcid":false,"given":"Marcela Camara","family":"Machado-Costa","sequence":"additional","affiliation":[{"name":"Escola Bahiana de Medicina e Sa\u00fade P\u00fablica, Salvador BA, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4589-2749","authenticated-orcid":false,"suffix":"Jr.","given":"Wilson","family":"Marques","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Neuroci\u00eancias e Ci\u00eancias do Comportamento, Ribeir\u00e3o Preto SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7304-0279","authenticated-orcid":false,"given":"Ciro","family":"Matsui Jr","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, Departamento de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7520-3353","authenticated-orcid":false,"given":"Rodrigo Holanda","family":"Mendon\u00e7a","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, Departamento de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8006-9435","authenticated-orcid":false,"given":"Fl\u00e1via","family":"Nardes","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Instituto de Puericultura e Pediatria Martag\u00e3o Gesteira, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6986-4937","authenticated-orcid":false,"given":"Acary Souza Bulle","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo, Departamento de Neurologia e Neurocirurgia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0043-5373","authenticated-orcid":false,"given":"Andre Luis Santos","family":"Pessoa","sequence":"additional","affiliation":[{"name":"Universidade Estadual do Cear\u00e1, Hospital Infantil Albert Sabin, Fortaleza CE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1141-6573","authenticated-orcid":false,"given":"Jonas Alex Morales","family":"Saute","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Hospital de Cl\u00ednicas de Porto Alegre, Servi\u00e7os de Gen\u00e9tica M\u00e9dica e de Neurologia, Porto Alegre RS, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7416-7108","authenticated-orcid":false,"given":"Paulo","family":"Sgobbi","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo, Departamento de Neurologia e Neurocirurgia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3123-2264","authenticated-orcid":false,"suffix":"Jr.","given":"H\u00e9lio","family":"Van der Linden","sequence":"additional","affiliation":[{"name":"Centro de Reabilita\u00e7\u00e3o Dr. Henrique Santillo, Servi\u00e7o de Neurologia Infantil e Neurofisiologia, Goi\u00e2nia GO, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3335-1491","authenticated-orcid":false,"given":"Juliana","family":"Gurgel-Giannetti","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Pediatria, Belo Horizonte MG, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"S Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"08","key":"ref2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal muscular atrophy: a timely review","volume":"68","author":"S J Kolb","year":"2011","journal-title":"Arch Neurol"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","article-title":"Spinal muscular atrophies","volume":"62","author":"B T Darras","year":"2015","journal-title":"Pediatr Clin North Am"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","article-title":"A positive modifier of spinal muscular atrophy in the SMN2 gene","volume":"85","author":"T W Prior","year":"2009","journal-title":"Am J Hum Genet"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"e33572","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","author":"T O Crawford","year":"2012","journal-title":"PLoS One"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","article-title":"Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next","volume":"21","author":"B Wirth","year":"2020","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"M R Lunn","year":"2008","journal-title":"Lancet"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000324156","article-title":"Detection of spinal muscular atrophy carriers in a sample of the Brazilian population","volume":"36","author":"K C Bueno","year":"2011","journal-title":"Neuroepidemiology"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"M Calucho","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"09","key":"ref10","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.3390\/ijms21093297","article-title":"New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?","volume":"21","author":"T H Chen","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/ebmed-2016-110401","article-title":"New evidence pyramid","volume":"21","author":"M H Murad","year":"2016","journal-title":"Evid Based Med"},{"issue":"08","key":"ref12","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00256-011-1145-z","article-title":"The Delphi method: an efficient procedure to generate knowledge","volume":"40","author":"J Steurer","year":"2011","journal-title":"Skeletal Radiol"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"E Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"M Feldk\u00f6tter","year":"2002","journal-title":"Am J Hum Genet"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.nmd.2006.08.011","article-title":"Multiplex ligation-dependent probe amplification improves diagnostics in spinal muscular atrophy","volume":"16","author":"E L Arkblad","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"ref16","first-page":"9.27.1","article-title":"Spinal Muscular Atrophy: Overview of Molecular Diagnostic Approaches","volume":"88","author":"T W Prior","year":"2016","journal-title":"Curr Protoc Hum Genet"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1212\/NXG.0000000000000505","article-title":"Intragenic variants in the SMN1 gene determine the clinical phenotype in 5q spinal muscular atrophy","volume":"6","author":"R H Mendon\u00e7a","year":"2020","journal-title":"Neurol Genet"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jmoldx.2020.01.015","article-title":"Survival Motor Neuron Gene Copy Number Analysis by Exome Sequencing: Assisting Spinal Muscular Atrophy Diagnosis and Carrier Screening","volume":"22","author":"B Liu","year":"2020","journal-title":"J Mol Diagn"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(95)90732-7","article-title":"PCR-based DNA test to confirm clinical diagnosis of autosomal recessive spinal muscular atrophy","volume":"345","author":"G van der Steege","year":"1995","journal-title":"Lancet"},{"key":"ref20","volume-title":"Spinal Muscular Atrophy. 2000 Feb 24 [updated 2020 Dec 3]","author":"T W Prior"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/mgg3.10","article-title":"A homozygous double mutation in SMN1: a complicated genetic diagnosis of SMA","volume":"1","author":"S M Kirwin","year":"2013","journal-title":"Mol Genet Genomic Med"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"C A Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"R S Finkel","year":"2016","journal-title":"Lancet"},{"issue":"18","key":"ref24","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"R S Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.nmd.2017.09.006","article-title":"Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience","volume":"27","author":"S Messina","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"09","key":"ref26","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/jnnp-2017-317412","article-title":"Nusinersen for SMA: expanded access programme","volume":"89","author":"M A Farrar","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"02","key":"ref27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/JND-180315","article-title":"Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany","volume":"5","author":"A Pechmann","year":"2018","journal-title":"J Neuromuscul Dis"},{"issue":"14","key":"ref28","doi-asserted-by":"publisher","first-page":"e1312","DOI":"10.1212\/WNL.0000000000006281","article-title":"Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study","volume":"91","author":"K Aragon-Gawinska","year":"2018","journal-title":"Neurology"},{"issue":"07","key":"ref29","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.nmd.2018.05.010","article-title":"Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function","volume":"28","author":"M Pane","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"03","key":"ref30","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/ana.25533","article-title":"Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data","volume":"86","author":"M Pane","year":"2019","journal-title":"Ann Neurol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jpeds.2019.12.047","article-title":"Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen","volume":"219","author":"V A Sansone","year":"2020","journal-title":"J Pediatr"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.prrv.2020.09.002","article-title":"Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-Year single centre Australian experience","volume":"39","author":"K A Chen","year":"2021","journal-title":"Paediatr Respir Rev"},{"issue":"02","key":"ref33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/JND-200533","article-title":"Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen","volume":"8","author":"R de Holanda Mendon\u00e7a","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"06","key":"ref34","doi-asserted-by":"publisher","first-page":"fcac269","DOI":"10.1093\/braincomms\/fcac269","article-title":"Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study","volume":"4","author":"F EV Scheijmans","year":"2022","journal-title":"Brain Commun"},{"issue":"08","key":"ref35","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.3390\/jcm12082839","article-title":"Effectiveness of Nusinersen in Type 1, 2 and 3 Spinal Muscular Atrophy: Croatian Real-World Data","volume":"12","author":"A Belan\u010di\u0107","year":"2023","journal-title":"J Clin Med"},{"issue":"19","key":"ref36","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1212\/WNL.0000000000206826","article-title":"Dysphagia and Lung Disease in Children With Spinal Muscular Atrophy Treated With Disease-Modifying Agents","volume":"100","author":"A Chacko","year":"2023","journal-title":"Neurology"},{"issue":"02","key":"ref37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.braindev.2022.10.006","article-title":"Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2","volume":"45","author":"H Iwayama","year":"2023","journal-title":"Brain Dev"},{"issue":"01","key":"ref38","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13023-023-02769-4","article-title":"Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience","volume":"18","author":"A \u0141usakowska","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"06","key":"ref39","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/ene.15768","article-title":"Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function","volume":"30","author":"M Pane","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00207454.2023.2251662","article-title":"Safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 524 patients: results from an interim analysis of post-marketing surveillance in Japan","volume":"\u2022\u2022\u2022","author":"Y Tachibana","year":"2023","journal-title":"Int J Neurosci"},{"issue":"07","key":"ref41","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"E Mercuri","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"ref42","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.3390\/jcm12154901","article-title":"Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor Function","volume":"12","author":"S Dunaway Young","year":"2023","journal-title":"J Clin Med"},{"issue":"04","key":"ref43","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/mus.26633","article-title":"Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy","volume":"60","author":"J Montes","year":"2019","journal-title":"Muscle Nerve"},{"issue":"04","key":"ref44","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3\u2014a prospective observational study","volume":"6","author":"M C Walter","year":"2019","journal-title":"J Neuromuscul Dis"},{"issue":"04","key":"ref45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"T Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1756286420907803","article-title":"Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen","volume":"13","author":"E Jochmann","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"issue":"04","key":"ref47","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1212\/WNL.0000000000009914","article-title":"Nusinersen in adult patients with spinal muscular atrophy: Observations from a single center","volume":"95","author":"O Moshe-Lilie","year":"2020","journal-title":"Neurology"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejpn.2020.05.002","article-title":"Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients","volume":"27","author":"L Szab\u00f3","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"issue":"02","key":"ref49","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/mus.26769","article-title":"Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience","volume":"61","author":"A Veerapandiyan","year":"2020","journal-title":"Muscle Nerve"},{"issue":"03","key":"ref50","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3233\/JND-190453","article-title":"Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy","volume":"7","author":"C JJ Yeo","year":"2020","journal-title":"J Neuromuscul Dis"},{"issue":"01","key":"ref51","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3233\/JND-200551","article-title":"Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience","volume":"8","author":"R H Mendon\u00e7a","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"08","key":"ref52","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1002\/acn3.51411","article-title":"Nusinersen in pediatric and adult patients with type III spinal muscular atrophy","volume":"8","author":"M C Pera","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"02","key":"ref54","doi-asserted-by":"publisher","first-page":"76","DOI":"10.36185\/2532-1900-074","article-title":"Muscle quantitative MRI in adult SMA patients on nusinersen treatment: a longitudinal study","volume":"41","author":"A Gallone","year":"2022","journal-title":"Acta Myol"},{"issue":"07","key":"ref55","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s10072-023-06698-9","article-title":"Nusinersen for adults with spinal muscular atrophy","volume":"44","author":"D Arslan","year":"2023","journal-title":"Neurol Sci"},{"issue":"07","key":"ref56","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1007\/s00415-023-11711-4","article-title":"An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy","volume":"270","author":"B Bjelica","year":"2023","journal-title":"J Neurol"},{"issue":"03","key":"ref57","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JND-221519","article-title":"Longitudinal Assessment of Timed Function Tests in Ambulatory Individuals with SMA Treated with Nusinersen","volume":"10","author":"K J Krosschell","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"01","key":"ref58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JND-221600","article-title":"Improvements in Walking Distance during Nusinersen Treatment - A Prospective 3-year SMArtCARE Registry Study","volume":"10","author":"A Pechmann","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"01","key":"ref59","doi-asserted-by":"publisher","first-page":"6240","DOI":"10.1038\/s41598-023-31617-5","article-title":"Improvement of muscle strength in specific muscular regions in nusinersen-treated adult patients with 5q-spinal muscular atrophy","volume":"13","author":"O Schreiber-Katz","year":"2023","journal-title":"Sci Rep"},{"issue":"05","key":"ref60","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s12519-022-00638-x","article-title":"Nusinersen for spinal muscular atrophy types II and III: a retrospective single-center study in South Korea","volume":"19","author":"H J Shin","year":"2023","journal-title":"World J Pediatr"},{"issue":"01","key":"ref61","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12883-023-03063-3","article-title":"Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study","volume":"23","author":"H Yang","year":"2023","journal-title":"BMC Neurol"},{"issue":"21","key":"ref62","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies","volume":"92","author":"B T Darras","year":"2019","journal-title":"Neurology"},{"issue":"07","key":"ref63","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2352-4642(21)00100-0","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study","volume":"5","author":"R S Finkel","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"01","key":"ref64","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis","volume":"16","author":"G Coratti","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"02","key":"ref65","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/medicina58020213","article-title":"The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"58","author":"K S Abbas","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"02","key":"ref66","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s13311-022-01200-3","article-title":"Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis","volume":"19","author":"M Gavriilaki","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1152318","DOI":"10.3389\/fped.2023.1152318","article-title":"Adverse events in the treatment of spinal muscular atrophy in children and adolescents with nusinersen: A systematic review and meta-analysis","volume":"11","author":"Z J Zhong","year":"2023","journal-title":"Front Pediatr"},{"issue":"05","key":"ref68","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JND-221667","article-title":"DEVOTE Study Exploring Higher Dose of Nusinersen in Spinal Muscular Atrophy: Study Design and Part A Results","volume":"10","author":"R S Finkel","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"11","key":"ref69","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"D C De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"02","key":"ref70","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"T O Crawford","year":"2023","journal-title":"Muscle Nerve"},{"issue":"15","key":"ref71","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)","volume":"61","author":"H Ratni","year":"2018","journal-title":"J Med Chem"},{"issue":"10","key":"ref72","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/nejmoa2009965","article-title":"Risdiplam in Type 1 Spinal Muscular Atrophy","volume":"384","author":"G Baranello","year":"2021","journal-title":"N Engl J Med"},{"issue":"05","key":"ref73","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/nejmoa2102047","article-title":"Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls","volume":"385","author":"B T Darras","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"ref74","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial","volume":"21","author":"R Masson","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref75","volume-title":"FIREFISH Parts 1 and 2: 48-month safety and efficacy of risdiplamin Type 1 SMA","author":"G Baranello"},{"issue":"07","key":"ref76","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1111\/ene.15499","article-title":"Risdiplam in types 2 and 3 spinal muscular atrophy: A randomized, placebo-controlled, dose-finding trial followed by 24 months of treatment","volume":"30","author":"E Mercuri","year":"2023","journal-title":"Eur J Neurol"},{"issue":"01","key":"ref77","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"E Mercuri","year":"2022","journal-title":"Lancet Neurol"},{"issue":"05","key":"ref78","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","article-title":"Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)","volume":"270","author":"M Oskoui","year":"2023","journal-title":"J Neurol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"e2.149","DOI":"10.1136\/jnnp-2022-abn2.232","article-title":"188 SUNFISH 3-year efficacy and safety of risdiplam in types 2 and 3 SMA","volume":"93","author":"L Servais","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"02","key":"ref80","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40120-023-00444-1","article-title":"Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study","volume":"12","author":"C A Chiriboga","year":"2023","journal-title":"Neurol Ther"},{"issue":"01","key":"ref81","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13023-022-02420-8","article-title":"Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany","volume":"17","author":"A Hahn","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"06","key":"ref82","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/acn3.51560","article-title":"An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy","volume":"9","author":"J M Kwon","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"05","key":"ref83","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mus.27804","article-title":"Risdiplam in non-sitter patients aged 16\u2009years and older with 5q spinal muscular atrophy","volume":"67","author":"N C \u00d1ungo Garz\u00f3n","year":"2023","journal-title":"Muscle Nerve"},{"issue":"02","key":"ref84","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27755","article-title":"Risdiplam for the treatment of adults with spinal muscular atrophy: Experience of the Northern Ireland neuromuscular service","volume":"67","author":"G McCluskey","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2866","article-title":"Efficacy of risdiplam in spinal muscular atrophy: A systematic review and meta-analysis","volume":"\u2022\u2022\u2022","author":"C Pascual-Morena","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"01","key":"ref87","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/acn3.51239","article-title":"Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy","volume":"8","author":"R C Sergott","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"06","key":"ref88","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/cpt.2384","article-title":"Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy","volume":"110","author":"Y Cleary","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"08","key":"ref89","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1111\/bcp.15319","article-title":"Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam","volume":"88","author":"H Kletzl","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"18","key":"ref90","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"J R Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"07","key":"ref91","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy","volume":"78","author":"J R Mendell","year":"2021","journal-title":"JAMA Neurol"},{"issue":"04","key":"ref92","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"J W Day","year":"2021","journal-title":"Lancet Neurol"},{"issue":"10","key":"ref93","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"E Mercuri","year":"2021","journal-title":"Lancet Neurol"},{"issue":"04","key":"ref94","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3233\/JND-221531","article-title":"Patients with Spinal Muscular Atrophy Type 1 Achieve and Maintain Bulbar Function Following Onasemnogene Abeparvovec Treatment","volume":"10","author":"K E McGrattan","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"03","key":"ref95","doi-asserted-by":"publisher","first-page":"e20200729","DOI":"10.1542\/peds.2020-0729","article-title":"Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes","volume":"146","author":"M A Waldrop","year":"2020","journal-title":"Pediatrics"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41434-021-00273-7","article-title":"Gene therapy for spinal muscular atrophy: the Qatari experience","volume":"28","author":"H G Ali","year":"2021","journal-title":"Gene Ther"},{"issue":"02","key":"ref97","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3233\/JND-200593","article-title":"Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience","volume":"8","author":"J Friese","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2021.01.012","article-title":"Clinical Experience With Gene Therapy in Older Patients With Spinal Muscular Atrophy","volume":"118","author":"S E Matesanz","year":"2021","journal-title":"Pediatr Neurol"},{"issue":"04","key":"ref99","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/mus.27375","article-title":"Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1","volume":"64","author":"K F Oechsel","year":"2021","journal-title":"Muscle Nerve"},{"issue":"03","key":"ref100","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/acn3.51519","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy","volume":"9","author":"A M D'Silva","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"04","key":"ref101","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.braindev.2021.12.006","article-title":"Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy","volume":"44","author":"S Lee","year":"2022","journal-title":"Brain Dev"},{"issue":"03","key":"ref102","doi-asserted-by":"publisher","first-page":"117","DOI":"10.36185\/2532-1900-077","article-title":"Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam","volume":"41","author":"M Tosi","year":"2022","journal-title":"Acta Myol"},{"issue":"01","key":"ref103","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","article-title":"Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15\u2009kg: an observational cohort study","volume":"6","author":"C Wei\u00df","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"04","key":"ref104","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/ppul.26285","article-title":"A breakthrough effect of gene replacement therapy on respiratory outcomes in children with spinal muscular atrophy","volume":"58","author":"A AlNaimi","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"101997","DOI":"10.1016\/j.eclinm.2023.101997","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in na\u00efve patients with spinal muscular atrophy and following switch from other therapies","volume":"59","author":"M Pane","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pediatrneurol.2023.04.007","article-title":"Real-Life Outcome After Gene Replacement Therapy for Spinal Muscular Atrophy: A Multicenter Experience","volume":"144","author":"I Tokatly Latzer","year":"2023","journal-title":"Pediatr Neurol"},{"issue":"01","key":"ref108","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12883-023-03133-6","article-title":"Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study","volume":"23","author":"G M Stettner","year":"2023","journal-title":"BMC Neurol"},{"issue":"03","key":"ref109","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/jpc.16340","article-title":"Safety and efficacy of gene therapy with onasemnogene abeparvovec in the treatment of spinal muscular atrophy: A systematic review and meta-analysis","volume":"59","author":"D Yang","year":"2023","journal-title":"J Paediatr Child Health"},{"issue":"07","key":"ref110","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"K A Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"07","key":"ref111","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"K A Strauss","journal-title":"Nat Med"},{"issue":"08","key":"ref112","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.nmd.2023.06.005","article-title":"Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial","volume":"33","author":"R D Shell","year":"2023","journal-title":"Neuromuscul Disord"},{"issue":"08","key":"ref113","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/s41436-020-0824-3","article-title":"Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy","volume":"22","author":"D M Kay","year":"2020","journal-title":"Genet Med"},{"issue":"01","key":"ref114","doi-asserted-by":"publisher","first-page":"19922","DOI":"10.1038\/s41598-021-99496-2","article-title":"Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium","volume":"11","author":"F Boemer","year":"2021","journal-title":"Sci Rep"},{"issue":"02","key":"ref115","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/ajmg.c.32003","article-title":"Georgia state spinal muscular atrophy newborn screening experience: Screening assay performance and early clinical outcomes","volume":"190","author":"K Elkins","year":"2022","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"12","key":"ref116","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/jnnp-2021-326344","article-title":"Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis","volume":"92","author":"S T Shih","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"01","key":"ref117","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1186\/s12887-022-03671-x","article-title":"Advances and limitations for the treatment of spinal muscular atrophy","volume":"22","author":"J W Day","year":"2022","journal-title":"BMC Pediatr"},{"issue":"03","key":"ref118","doi-asserted-by":"publisher","first-page":"e36197","DOI":"10.7759\/cureus.36197","article-title":"Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma)","volume":"15","author":"T Ogbonmide","year":"2023","journal-title":"Cureus"},{"issue":"14","key":"ref119","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"J Guillou","year":"2022","journal-title":"Blood Adv"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma","volume":"33","author":"A Philippidis","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"09","key":"ref121","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/jcpt.13733","article-title":"Hemophagocytic lymphohistiocytosis following gene replacement therapy in a child with type 1 spinal muscular atrophy","volume":"47","author":"F Galletta","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"113493","DOI":"10.1016\/j.jpeds.2023.113493","article-title":"Necrotizing Enterocolitis following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series","volume":"260","author":"J Gaillard","year":"2023","journal-title":"J Pediatr"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.omtm.2021.02.014","article-title":"Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec","volume":"21","author":"J W Day","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"03","key":"ref124","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3233\/JND-221560","article-title":"Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)","volume":"10","author":"R S Finkel","year":"2023","journal-title":"J Neuromuscul Dis"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"38","DOI":"10.31128\/AJGP-03-21-5924","article-title":"The changing therapeutic landscape of spinal muscular atrophy","volume":"51","author":"J E Davidson","year":"2022","journal-title":"Aust J Gen Pract"},{"issue":"04","key":"ref126","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3233\/JND-200617","article-title":"A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method","volume":"8","author":"J Slayter","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"01","key":"ref127","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13023-019-0998-4","article-title":"SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy","volume":"14","author":"A Pechmann","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"04","key":"ref128","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3233\/JND-200534","article-title":"Measuring Outcomes in Adults with Spinal Muscular Atrophy - Challenges and Future Directions - Meeting Report","volume":"7","author":"V A Sansone","year":"2020","journal-title":"J Neuromuscul Dis"},{"issue":"04","key":"ref129","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/mus.20018","article-title":"Motor function-muscle strength relationship in spinal muscular atrophy","volume":"29","author":"L Merlini","year":"2004","journal-title":"Muscle Nerve"},{"issue":"04","key":"ref130","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.nmd.2021.01.008","article-title":"A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs","volume":"31","author":"L Edel","year":"2021","journal-title":"Neuromuscul Disord"},{"issue":"03","key":"ref131","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.nrleng.2021.07.002","article-title":"Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus)","volume":"37","author":"I Pitarch Castellano","year":"2022","journal-title":"Neurolog\u00eda (Engl Ed)"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.sleep.2022.11.006","article-title":"Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec","volume":"101","author":"C Leon-Astudillo","year":"2023","journal-title":"Sleep Med"},{"issue":"01","key":"ref133","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/ppul.26173","article-title":"Respiratory characteristics in children with spinal muscular atrophy type 1 receiving nusinersen","volume":"58","author":"L Xiao","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"04","key":"ref134","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1212\/WNL.0b013e31827f07be","article-title":"Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy","volume":"80","author":"B M Kluger","year":"2013","journal-title":"Neurology"},{"issue":"06","key":"ref135","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.nmd.2022.04.003","article-title":"Longer-term follow-up of nusinersen efficacy and safety in adult patients with spinal muscular atrophy types 2 and 3","volume":"32","author":"Y Fainmesser","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1756286421998902","article-title":"Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy","volume":"14","author":"A Osmanovic","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.2147\/IJGM.S369021","article-title":"Experience and perspectives in the US on the evolving treatment landscape in Spinal Muscular Atrophy","volume":"15","author":"L Ramos-Platt","year":"2022","journal-title":"Int J Gen Med"},{"issue":"04","key":"ref139","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3233\/JND-200610","article-title":"Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada","volume":"8","author":"H J McMillan","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"04","key":"ref140","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/mus.27363","article-title":"Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy","volume":"64","author":"E A Kichula","year":"2021","journal-title":"Muscle Nerve"},{"issue":"23","key":"ref141","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.3390\/jcm10235540","article-title":"Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I","volume":"10","author":"A Mirea","year":"2021","journal-title":"J Clin Med"},{"issue":"01","key":"ref142","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"E A Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"issue":"12","key":"ref143","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/s41431-019-0415-4","article-title":"Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors","volume":"27","author":"C Serra-Juhe","year":"2019","journal-title":"Eur J Hum Genet"},{"issue":"10","key":"ref144","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1038\/s41431-018-0193-4","article-title":"Utility of two SMN1 variants to improve spinal muscular atrophy carrier diagnosis and genetic counselling","volume":"26","author":"L Al\u00edas","year":"2018","journal-title":"Eur J Hum Genet"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"7S9","DOI":"10.1016\/S0929-693X(20)30270-0","article-title":"Molecular diagnosis and genetic counseling for spinal muscular atrophy (SMA)","volume":"27","author":"C Rouzier","year":"2020","journal-title":"Arch Pediatr"},{"issue":"07","key":"ref146","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/genes14071377","article-title":"Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening-A Systematic Review","volume":"14","author":"K Aragon-Gawinska","year":"2023","journal-title":"Genes (Basel)"},{"issue":"07","key":"ref147","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00431-023-04883-8","article-title":"New therapies for spinal muscular atrophy: where we stand and what is next","volume":"182","author":"L Antonaci","year":"2023","journal-title":"Eur J Pediatr"},{"issue":"01","key":"ref148","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3233\/JND-190441","article-title":"Treatment with Nusinersen - Challenges Regarding the Indication for Children with SMA Type 1","volume":"7","author":"A Pechmann","year":"2020","journal-title":"J Neuromuscul Dis"},{"issue":"02","key":"ref149","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JND-190468","article-title":"Revised Recommendations for the Treatment of Infants Diagnosed with Spinal Muscular Atrophy Via Newborn Screening Who Have 4 Copies of SMN2","volume":"7","author":"J Glascock","year":"2020","journal-title":"J Neuromuscul Dis"},{"issue":"06","key":"ref150","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/ana.26788","article-title":"Clinical phenotype of paediatric and adult patients with spinal muscular atrophy with 4 SMN2 copies: are they really all stable?","volume":"94","author":"M Ricci","year":"2023","journal-title":"Ann Neurol"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.pediatrneurol.2022.04.008","article-title":"Nusinersen for Patients With Spinal Muscular Atrophy: 1415 Doses via an Interdisciplinary Institutional Approach","volume":"132","author":"E Madan","year":"2022","journal-title":"Pediatr Neurol"},{"issue":"02","key":"ref152","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40263-022-00899-0","article-title":"Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model","volume":"36","author":"D MacCannell","year":"2022","journal-title":"CNS Drugs"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pediatrneurol.2022.05.001","article-title":"Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5\u2009kg or Heavier in a Global Managed Access Program","volume":"132","author":"D H Chand","year":"2022","journal-title":"Pediatr Neurol"},{"issue":"06","key":"ref155","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.bbmt.2016.02.020","article-title":"Association of Cumulative Steroid Dose with Risk of Infection after Treatment for Severe Acute Graft-versus-Host Disease","volume":"22","author":"Y Matsumura-Kimoto","year":"2016","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1779503.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:48:40Z","timestamp":1730818120000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1779503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":150,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,1,25]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["s00441779503"],"URL":"https:\/\/doi.org\/10.1055\/s-0044-1779503","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}